MEDI-LINE S.A.

Liege Science Park
Rue des Gardes Frontières, 5
4031 ANGLEUR (LIEGE)
BELGIUM

Tél . : +32 (0) 4 366 02 78
Fax : +32 (0) 4 366 02 07

TOM-Sling® solution

Features & Benefits

The Tom-Sling is a device developed for compressing the bulbar urethra in order to treat disabling urinary incontinence from mild to severe in men after radical prostatectomy and failure of conservative treatment for more than 12 months.

The TOM-Sling kit contains the following elements :

  • 1 mesh implant (polypropylene) including a central part and two arms,
  • 1 pair of passers,
  • 1 winged guide,
  • 1 pair of flexible tubes,
  • 1 pair pullwires tubes,
Kit Tom Sling

Tom-Sling is a prosthetic polypropylene, knitted, monofilament non-absorbable mesh.  

The TOM-sling placement is much less invasive than the surgery for the placement of an artificial urinary sphincter (AUS) or other slings. The use of the TOM-Sling has a much lower rate of complication and infections and it works with high efficiency without patient intervention regardless of age. Finally, the placement of an artificial urinary sphincter can cause a tissues atrophy and thus reduce its efficiency. With bulbar urethra compression sling like the TOM-Sling, this problem does not exist.

 

The benefits of the TOM-Sling :

  • High success rate for the treatment of SUI from mild to severe,
  • Minimally invasive surgical procedure (perineal incision),
  • No tissue atrophy,
  • Compression of the bulbar urethra is maintained by solidarisation of the two transobturartor arms of the prosthesis,
  • Safe transobturator path by the use of a guide (reducing the risk of bladder perforation)
  • No dissection of the bulbospongious muscle (reducing theoretically the risk of urethral erosion by the prosthetic material),
  • No fixation of the mesh to the urethra or osseous structures.

 

Follow TOM-Sling press release in English :

Mediline

The TOM-Sling® is a medical device for the treatment of male urinary incontinence, manufactured and distributed by  MEDI-LINE company, developed by the Professor J. de Leval et D. Waltregny from the University Hospital of Liège and the University of Liège.